How is the 102,000-share grant to the Artiva Biotherapeutics (ARTV) CMO characterized?

The 102,000-share transaction is characterized as a grant, award, or other acquisition of common stock. A footnote explains that it represents a restricted stock unit award granted under Artiva Biotherapeutics’ 2024 Equity Incentive Plan, rather than an open-market purchase of existing shares.

Artiva CMO granted 102,000-share equity award

Artiva Biotherapeutics, Inc. reported that its Chief Medical Officer, Subhashis Banerjee, acquired 102,000 shares of common stock through a grant described as a restricted stock unit award under the company’s 2024 Equity Incentive Plan.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Artiva Biotherapeutics, Inc. reported that its Chief Medical Officer, Subhashis Banerjee, acquired 102,000 shares of common stock through a grant described as a restricted stock unit award under the company’s 2024 Equity Incentive Plan. Following this equity award, his directly held common stock ownership increased to 152,000 shares.

Insider Trade Summary

Grant/Award: 102,000 shares

Grant/Award 1 txn

Insider Banerjee Subhashis

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	102,000	$0.00	$0.00

Holdings After Transaction: Common Stock — 152,000 shares (Direct)

Footnotes (1)

F1. Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Artiva Biotherapeutics (ARTV) report in this Form 4 for Subhashis Banerjee?

The Form 4 reports that Chief Medical Officer Subhashis Banerjee received 102,000 shares of common stock as a restricted stock unit award, granted under Artiva Biotherapeutics’ 2024 Equity Incentive Plan, increasing his directly held ownership to 152,000 shares.

How many Artiva Biotherapeutics (ARTV) shares did the CMO acquire in this Form 4?

Subhashis Banerjee acquired 102,000 shares of Artiva Biotherapeutics common stock. The filing classifies this as a grant, award, or other acquisition, specifically a restricted stock unit award issued under the company’s 2024 Equity Incentive Plan at a stated price of $0.0000 per share.

What is Subhashis Banerjee’s Artiva Biotherapeutics (ARTV) ownership after this transaction?

After the reported transaction, Chief Medical Officer Subhashis Banerjee directly owns 152,000 shares of Artiva Biotherapeutics common stock. This total reflects the addition of the newly granted 102,000 restricted stock unit award under the company’s 2024 Equity Incentive Plan reported in the Form 4.

Does the Artiva Biotherapeutics (ARTV) Form 4 indicate a purchase or an equity award?

The Form 4 indicates an equity award, not a market purchase. The transaction code is “A” for grant, award, or other acquisition, and a footnote clarifies that the 102,000 shares represent a restricted stock unit award under the Artiva Biotherapeutics 2024 Equity Incentive Plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 02/18/2026 - 06:48 PM EST

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Banerjee Subhashis

(Last)

(First)

(Middle)

C/O ARTIVA BIOTHERAPEUTICS, INC.

5505 MOREHOUSE DRIVE, SUITE 100

(Street)

SAN DIEGO

92121

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Artiva Biotherapeutics, Inc. [ ARTV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/15/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/15/2026		A		102,000⁽¹⁾	A	$0	152,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan.

	/s/ Andrew Cronauer, Attorney-in-Fact	02/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR